Effect of Cardiac Protection with Intralipid after Insult during Off-Pump Coronary Artery Bypass Surgery

Phase 4

Completed

• Conditions: Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryHealth Condition 2: I25- Chronic ischemic heart diseaseHealth Condition 3: I20-I25- Ischemic heart diseasesHealth Condition 4: I24- Other acute ischemic heart diseases

• Registration Number: CTRI/2023/11/060068
• Lead Sponsor: All India Institute of Medical Sciences, Bathinda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients posted for elective Off Pump Coronary Artery Bypass Surgery (OPCAB) with left ventricular ejection fraction (LVEF) > 40 %

Exclusion Criteria

Combined valve and coronary surgery, onpump CABG, redo cardiac surgery, hyperlipidaemia, significant hepatic or renal dysfunction, uncontrolled hypertension, any disorder with immunological dysfunction (eg, malignancy or positive serological test for the HIV) in the last 6 months, preoperative treatment with nicorandil (an ATP-sensitive potassium channel opener), sulfonylurea (an ATP- sensitive potassium channel blocker)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the cardioprotective role of Intralipid (IL) by assessing Troponin I postoperatively 6th hourly, 24th hourly, 48th hourly and 72th hourly.Timepoint: To evaluate the cardioprotective role of Intralipid (IL) by assessing Troponin I postoperatively 6th hourly, 24th hourly, 48th hourly and 72th hourly.

Secondary Outcome Measures

Name	Time	Method
VEFTimepoint: at time of discharge;to estimate the clinical effect of inotropic useTimepoint: Intraoperatively , POD-1 and POD-2;To find out the effect of intralipid on the serum levels of blood lipids, serum creatinine and total bilirubin.Timepoint: preoperatively, postoperatively POD1 and POD2;to find out the effector intralipid on the ventilatory hours and length of ICU stay post-operativelyTimepoint: Postoperative period;to find out the hemodynamic effect of intralipid on systemic circulationTimepoint: intraoperativelyafter initiating intralipid infusion at 0, 1 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min and post-operatively after shifting;To find out the outcome on the complications occurring during hospitalisation including arrhythmias, stroke, infection, respiratory failure, hepatic or renal failure, reoperation and mortality will be notedTimepoint: intra-operative period and post-operative period